Adaptimmune Therapeutics plc (473A) — Cash Flow Reinvestment Rate

Latest as of June 2024: 0.03x

Adaptimmune Therapeutics plc (473A) has a Cash Flow Reinvestment Rate of 0.03x as of June 2024, reinvesting €1.50 Million (capex €754.00K plus investments €-743.00K) from operating cash flow of €47.40 Million. Explore Adaptimmune Therapeutics plc capital spending ratio to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

0.03x

(Capex + Investments) / Operating CF

Total Reinvested

€1.50 Million

Capex + Investments

Operating Cash Flow

€47.40 Million

EUR

Capital Expenditures

€754.00K

EUR

Adaptimmune Therapeutics plc Cash Flow Reinvestment Rate (2021–2021)

Historical reinvestment intensity for Adaptimmune Therapeutics plc across 1 annual periods. Also explore total assets of Adaptimmune Therapeutics plc for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for Adaptimmune Therapeutics plc (2021–2021)

Year-by-year capital reinvestment analysis for Adaptimmune Therapeutics plc. For live market cap and broader valuation context, see market cap of Adaptimmune Therapeutics plc.

Year	Reinvestment Rate	Total Reinvested (EUR)	Operating CF	Capex	YoY Change
2021	8.68x	€93.16 Million	€10.73 Million	€8.57 Million	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow